EBR Systems Seeks Medicare Reimbursement for WiSE CRT System

EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) just unveiled an update.

EBR Systems, Inc. has submitted an application to the U.S. Centers for Medicare & Medicaid Services for the Transitional Pass-Through reimbursement scheme for their WiSE CRT System. This move follows recent FDA approval and aims to facilitate hospital adoption of the system by providing a clear reimbursement pathway for outpatients. If approved, the scheme will be effective from October 2025, enhancing Medicare payments for hospitals and supporting the commercial rollout of the WiSE CRT System in the U.S. The CMS has already recommended the system for New Technology Add-On Payment for inpatients, indicating strong support for EBR’s innovative technology.

More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

Silicon Valley-based EBR Systems, Inc. specializes in cardiac rhythm disease treatment through its innovative wireless cardiac pacing technology. The company’s WiSE technology eliminates the need for traditional cardiac pacing leads, addressing complications and reliability issues. Their primary product is the WiSE CRT System, designed for heart failure patients requiring Cardiac Resynchronization Therapy, with future potential applications for bradycardia and other non-cardiac indications.

YTD Price Performance: 24.02%

Average Trading Volume: 891,549

For a thorough assessment of EBR stock, go to TipRanks’ Stock Analysis page.